ETRM : Summary for EnteroMedics Inc. - Yahoo Finance

U.S. Markets close in 2 hrs 44 mins

EnteroMedics Inc. (ETRM)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.08+0.02 (+43.52%)
As of 1:16 PM EST. Market open.
People also watch:
MSTXSKLNIMNPCPRXAMDA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.05
Open0.06
Bid0.07 x 7200
Ask0.07 x 1400
Day's Range0.05 - 0.08
52 Week Range0.04 - 2.70
Volume37,812,386
Avg. Volume8,731,146
Market Cap8.77M
Beta2.20
PE Ratio (TTM)-0.05
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire8 days ago

    EnteroMedics to Host vBloc® Therapy Commercialization and Corporate Update Conference Call

    ST. PAUL, Minn., Nov. 30, 2016 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a vBloc® Therapy commercialization and corporate update conference call today at 11:00 AM Eastern Time ahead of the Company's anticipated special meeting of shareholders to be held Monday, December 12, 2016. The call will be led by Dan W. Gladney, the Company's President, Chief Executive Officer and Chairman of the Board. To access the live webcast, visit the events page of the investor relations section of EnteroMedics' website at www.enteromedics.com.

  • PR Newswire16 days ago

    EnteroMedics Provides Commercialization and Corporate Update

    ST. PAUL, Minn., Nov. 22, 2016 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today provided an overview of its recent commercialization and corporate achievements, and announced it will host a conference call on Wednesday, November 30, 2016 at 11:00 AM Eastern Time ahead of the Company's anticipated special meeting of shareholders to be held Monday, December 12, 2016. The call will be led by Dan W. Gladney, the Company's President, Chief Executive Officer and Chairman of the Board. "Throughout the past year, EnteroMedics has made several important advances in our commercialization strategy and our goal of securing broad reimbursement coverage to ensure vBloc Therapy is widely available to all patients," said Dan Gladney, EnteroMedics' President, Chief Executive Officer and Chairman of the Board.

  • EnteroMedics, Inc. :ETRM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016
    Capital Cube27 days ago

    EnteroMedics, Inc. :ETRM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016

    Categories: Yahoo Finance Get free summary analysis EnteroMedics, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of EnteroMedics, Inc. – LivaNova Plc, Boston Scientific Corporation, NeuroMetrix, Inc., St. Jude Medical, Inc., Johnson & Johnson, Natus Medical Incorporated and Abbott Laboratories (LIVN-US, BSX-US, NURO-US, STJ-US, JNJ-US, BABY-US ... Read more (Read more...)